CAY-10599 is a potent and selective inhibitor of cytosolic phospholipase A2 alpha (cPLA2α), a key enzyme in arachidonic acid release and eicosanoid biosynthesis. It is primarily utilized in research settings to study its effects on cellular processes, particularly in the context of inflammation, cancer, and related signaling pathways. By modulating cPLA2α activity, it serves as a valuable tool for understanding molecular mechanisms involved in disease progression, including cell survival, proliferation, and immune responses. Researchers employ it to investigate its potential as a therapeutic agent, focusing on its ability to inhibit key proteins in these pathways. Additionally, CAY-10599 is used in preclinical studies to evaluate its efficacy, safety, and toxicity in animal models, providing insights into its potential for future drug development in targeted therapies and personalized medicine.